In vitro and in vivo characterization of the JAK1 selectivity of upadacitinib (ABT-494)

BACKGROUND: Anti-cytokine therapies such as adalimumab, tocilizumab, and the small molecule JAK inhibitor tofacitinib have proven that cytokines and their subsequent downstream signaling processes are important in the pathogenesis of rheumatoid arthritis. Tofacitinib, a pan-JAK inhibitor, is the fir...

Descripción completa

Detalles Bibliográficos
Autores principales: Parmentier, Julie M., Voss, Jeff, Graff, Candace, Schwartz, Annette, Argiriadi, Maria, Friedman, Michael, Camp, Heidi S., Padley, Robert J., George, Jonathan S., Hyland, Deborah, Rosebraugh, Matthew, Wishart, Neil, Olson, Lisa, Long, Andrew J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2018
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390583/
https://www.ncbi.nlm.nih.gov/pubmed/30886973
http://dx.doi.org/10.1186/s41927-018-0031-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6390583/
https://www.ncbi.nlm.nih.gov/pubmed/30886973
http://dx.doi.org/10.1186/s41927-018-0031-x

Ejemplares similares